The analysis of the methylation profile of CMML patients with a hypomethylated JAK2 -which could be associated with an increased expression of this gene- in comparison with healthy controls showed only 13 CpGs differentially methylated between both groups which were not differentially distributed between JAK2V617F CMML, JAK2 wild type CMML and control samples (data not shown). This evidence concerns the gene JAK2 and chronic myelomonocytic leukemia.